As of 2025-04-23, the Relative Valuation of BridgeBio Pharma Inc (BBIO) is (49.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 34.18 USD, the upside of BridgeBio Pharma Inc based on Relative Valuation is -243.4%.
The range of the Relative Valuation is (42.09) - (66.09) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 26.9x | 16.7x |
| Forward P/E multiples | 14.4x - 23.5x | 18.1x |
| Fair Price | (42.09) - (66.09) | (49.02) |
| Upside | -223.1% - -293.3% | -243.4% |
| Date | P/E |
| 2025-04-22 | -12.13 |
| 2025-04-21 | -11.90 |
| 2025-04-17 | -12.02 |
| 2025-04-16 | -12.02 |
| 2025-04-15 | -12.15 |
| 2025-04-14 | -12.37 |
| 2025-04-11 | -12.04 |
| 2025-04-10 | -11.47 |
| 2025-04-09 | -11.67 |
| 2025-04-08 | -10.70 |
| 2025-04-07 | -10.89 |
| 2025-04-04 | -11.14 |
| 2025-04-03 | -12.09 |
| 2025-04-02 | -12.29 |
| 2025-04-01 | -11.72 |
| 2025-03-31 | -12.27 |
| 2025-03-28 | -12.46 |
| 2025-03-27 | -12.92 |
| 2025-03-26 | -12.82 |
| 2025-03-25 | -13.04 |
| 2025-03-24 | -13.21 |
| 2025-03-21 | -12.34 |
| 2025-03-20 | -12.04 |
| 2025-03-19 | -11.98 |
| 2025-03-18 | -11.43 |
| 2025-03-17 | -11.72 |
| 2025-03-14 | -11.70 |
| 2025-03-13 | -11.47 |
| 2025-03-12 | -11.57 |
| 2025-03-11 | -11.48 |
| 2025-03-10 | -11.15 |
| 2025-03-07 | -11.21 |
| 2025-03-06 | -11.44 |
| 2025-03-05 | -12.41 |
| 2025-03-04 | -11.91 |
| 2025-03-03 | -11.72 |
| 2025-02-28 | -12.39 |
| 2025-02-27 | -12.16 |
| 2025-02-26 | -11.87 |
| 2025-02-25 | -12.19 |
| 2025-02-24 | -12.87 |
| 2025-02-21 | -13.08 |
| 2025-02-20 | -13.07 |
| 2025-02-19 | -12.88 |
| 2025-02-18 | -12.60 |
| 2025-02-14 | -12.39 |
| 2025-02-13 | -11.20 |
| 2025-02-12 | -11.34 |
| 2025-02-11 | -11.05 |
| 2025-02-10 | -11.27 |